

Pressrelease

The County Council of Värmland first in Sweden to implement a digital care pathway for arrhythmia investigation

Stockholm September 27, 2018

The County Council of Värmland and Zenicor Medical Systems AB have together developed a model for a more effective care pathway for arrhythmia investigations. All of the County's primary care centers will offer the service in order to offer patients early diagnosis of atrial fibrillation.

- *Zenicor is not only a supplier of products but also contributes to the development and efficiency of the care pathway. We have worked together with the County Council of Värmland for a long time on how digitalization can help to develop a new care pathway for arrhythmia investigation. The fact that Värmland now is implementing this throughout the primary care is a sign that they see the benefits for the society that early diagnosis of atrial fibrillation implies. At the same time, it consolidates Zenicor's position as a leader within early diagnosis and stroke prevention for healthcare. Says Mats Palerius, CEO at Zenicor Medical Systems AB.*

The agreement with the County Council of Värmland can be directly attributed to the work which Zenicor previously has carried out in the two Finnish Counties of Oulu and Tempere. The model of optimizing the care pathway in primary care provides new and increased revenues as this model is spread to additional County Councils in Sweden and internationally.

Värmland is the first County Council in Sweden to implement a digital care pathway for arrhythmia investigations and early diagnosis for atrial fibrillation. The decision to introduce the new digital care pathway with Zenicor-ECG has been made by the health care administration in Värmland. Zenicor's optimized care pathway for arrhythmia investigation provides early diagnosis, which enables earlier treatment.

Anders Eriksson, Operations Manager at Clinical Physiology in Karlstad comments;

- *The digitalized care pathway shortens waiting times and reduces travel for the patients. It is a win-win situation for us, the patient and the referral primary care center.*

The new and improved/efficient care pathway is a combination of a physical meeting with the patient and digitalization;

1. Patients with symptoms has their point of contact at the primary care center where they receive a Zenicor-ECG to take home and measure for a 2-week period from/at home.
2. The measurements are sent digitally from the patient's Zenicor-ECG directly to the central interpretation at Clinical Physiology at the Karlstad Hospital.
3. Diagnosis is made by specialists at Clinical Physiology in Karlstad and transferred to the primary care center who contacts the patient for further treatment.

The improved care pathway means that:

- More people in Sweden will be able to be investigated for atrial fibrillation.
- Zenicor-ECG is already handed out at the patient's primary care visit.
- Reduced waiting times and increased accessibility for the patient.
- Reduced need for referral to another health care provider.
- Reduced paperwork as ECG can be interpreted remotely by specialists in Cardiology.

Pressrelease

About Zenicor and thumb-ECG from Zenicor

Zenicor Medical Systems is a leading company in arrhythmia and stroke prevention. Zenicor's ECG is a system optimized for cardiac arrhythmia diagnosis, including atrial fibrillation in healthcare, and today it is used in over 400 clinics in 10 countries in Europe. The efficiency of the solution has been documented in a number of studies and articles in internationally leading scientific journals. These studies have shown that Zenicor's ECG has a superior diagnostic ability, combined with cost-effectiveness and ease of use compared to traditional methods.

For further information, please contact:

Mats Palerius, CEO, Zenicor Medical Systems AB,

Phone: +46 70 561 55 64

E-mail: mats@zenicor.se

High resolution images of Zenicor ECG are available for download:

<https://zenicor.com/press-material/>

This information is such information as Zenicor is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on September 27, 2018.

